Latest Content

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

Dive into poetic reflections on life and aging.

Explore the profound reflections of AI on human experiences, emotions, and the potential impact of chatbots in therapy and daily life.